Lung cancer

October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

Retrieved on: 
Friday, October 20, 2023
Science, Survival, FDA, University of Pittsburgh School of Medicine, Associate, Clinical professor, Life, Internet, Lung cancer, Literature, Physician, Mortality, News, Doctor of Philosophy, Breast Cancer Awareness Month, Breast cancer, CPI, TNBC, ClinicalTrials.gov, Trust, Letter, Life expectancy, Disease, Risk, Partnership, University of Pittsburgh, Personalized medicine, Immunotherapy, University, Sandra, Figure, Woman, Wilfrid Sellars, Fast track (FDA), FACP, Cancer, Therapy, BCT, Weill Cornell Medicine, Diagnosis, Patient, TSX, Mayo Clinic, Liquor, Pharmaceutical industry, Birth control, Medical imaging, MD

The overall risk of a woman in the United States developing breast cancer sometime in her life is about 13%.

Key Points: 
  • The overall risk of a woman in the United States developing breast cancer sometime in her life is about 13%.
  • This means there is an approximately 1 in 8 chance she will develop breast cancer;
    Approximately 43,170 women and 530 men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of cancer death in women (after lung cancer) in the U.S.
  • I am writing this letter during Breast Cancer Awareness month to alert all to the devastation of advanced breast cancer.
  • While the focus of the month is on early detection, as it should be, I highlight our recent accomplishments in the fight against advanced breast cancer, an incurable disease.

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Retrieved on: 
Thursday, October 19, 2023
NSCLC, FTI, Therapy, Lung cancer, Protein, HRAS, Pharmacokinetics, KURA, Carcinoma, Safety, Cancer, Renal cell carcinoma, SAN, EGFR, Pharmaceutical industry

SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in the FIT-001 Phase 1 dose-escalation trial of KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumors.

Key Points: 
  • SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in the FIT-001 Phase 1 dose-escalation trial of KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumors.
  • “We’re excited to advance our next-generation FTI drug candidate into the clinical setting, underscoring our commitment and sense of urgency to develop novel therapies for cancer indications with high unmet medical needs,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • “Our understanding of how to use FTIs to target farnesylated proteins has matured significantly beyond our initial strategy to target HRAS mutant tumors.
  • For more information regarding FIT-001, please visit www.clinicaltrials.gov (identifier: NCT06026410 ).

Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer's Disease Biomarker Research at CTAD Conference

Retrieved on: 
Wednesday, October 25, 2023
Research, Other Health, General Health, Oncology, Biometrics, Mental Health, Technology, Artificial Intelligence, Science, Neurology, Biotechnology, Health, Other Science, Biomarker, RNA, Lung cancer, Clinical trial, Disease, Immune system, Risk, EPAD, Machine learning, Diagnosis, Medical imaging, Alzheimer's disease

Hummingbird Diagnostics GmbH, a leader in blood-based small RNA detection and characterization, today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston.

Key Points: 
  • Hummingbird Diagnostics GmbH, a leader in blood-based small RNA detection and characterization, today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston.
  • The company has applied its state-of-the-art “mirCator” platform to answer critical questions related to Alzheimer's disease.
  • “We’re thrilled to present our latest research at CTAD, one of the world’s leading conferences on Alzheimer’s disease,” said Dr. Bruno Steinkraus, Chief Scientific Advisor at Hummingbird Diagnostics.
  • “It combines proprietary wet lab innovations, largely automated workflows and advanced machine learning data analysis to deliver unprecedented technical performance.”

Global Peptide Drug Conjugates Market Expected to Reach $4.21 Billion by 2030, Driven by Rising Cancer Cases - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Health, Pharmaceutical, WHO, FDA, Clinical trial, Multiple myeloma, Lung cancer, Mortality, Carcinoma, Christian democracy, Death, Wuxi, Lutetium (177Lu) oxodotreotide, Growth, Novartis, World Health Organization, PDC, Partnership, Brain, USD, Cancer, ANG1005, Somatostatin, Melphalan, Compound annual growth rate, Fine chemical, Pharmaceutical industry

The global peptide drug conjugates market is poised for significant growth, with an expected value of USD 4.21 billion by 2030, registering a remarkable Compound Annual Growth Rate (CAGR) of 28.58% during the forecast period.

Key Points: 
  • The global peptide drug conjugates market is poised for significant growth, with an expected value of USD 4.21 billion by 2030, registering a remarkable Compound Annual Growth Rate (CAGR) of 28.58% during the forecast period.
  • Rising Cancer Cases: The market's growth is driven by the global surge in cancer cases and related mortality.
  • The increasing demand for novel treatments like peptide drug conjugates (PDCs) to target uncontrolled cell growth is expected to fuel market growth.
  • For instance, in December 2021, Coherent Biopharma and WuXi STA announced a strategic partnership agreement to develop their current and future therapeutic drugs, including peptide drug conjugates.

Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, October 24, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, FDA, Pulmonary fibrosis, Pneumonitis, NHLBI, Lung cancer, Small Business Innovation Research, SBIR, Idiopathic pulmonary fibrosis, National Heart, Lung, and Blood Institute, BIO, Inflammation, IPF, Quality of life, Radiation, Lung, Disease, Clinical trial, COVID-19, Therapy, Defense, Patient, Diagnosis, Injury, Bangladesh Technical Education Board, United States Department of Defense, Pharmaceutical industry, Humanetics

The funding will support a series of studies with its new drug candidate, BIO 300.

Key Points: 
  • The funding will support a series of studies with its new drug candidate, BIO 300.
  • The studies will focus on the ability of BIO 300 to attenuate progressive pulmonary fibrosis as a potential treatment for idiopathic pulmonary fibrosis (IPF).
  • Notably, the drug has been shown to mitigate inflammation of the lungs (pneumonitis) and pulmonary fibrosis caused by radiation.
  • Humanetics further expanded applications for the drug into cancer radiation therapy, COVID-19, and other inflammatory pulmonary diseases.

TailorMed Partners with Eagle Pharmaceuticals to Streamline Patient Financial Assistance Enrollment

Retrieved on: 
Tuesday, October 24, 2023
Health Technology, Health Insurance, Insurance, Technology, Finance, Practice Management, Apps, Applications, Oncology, Managed Care, Professional Services, General Health, Hospitals, Software, Networks, Health, Medicine, Lung cancer, Pharmacy technician, Ecosystem, Partnership, Hospital, API, Pharmacy, Express, Cancer, Patient, Nursing

With Express Enroll, providers and pharmacies within the TailorMed network can now complete Pemfexy Copay Assistance Program enrollments through a fully digital process, without leaving the TailorMed platform.

Key Points: 
  • With Express Enroll, providers and pharmacies within the TailorMed network can now complete Pemfexy Copay Assistance Program enrollments through a fully digital process, without leaving the TailorMed platform.
  • These capabilities will empower TailorMed users to complete Pemfexy Copay Assistance Program enrollments quickly and efficiently, supporting stronger patient experiences and medication adherence.
  • “This partnership with TailorMed underscores our commitment to supporting patient access to Pemfexy,” said William Kim, VP of Market Access, Oncology at Eagle Pharmaceuticals.
  • We’re proud to partner with Eagle Pharmaceuticals to help further patient enrollment and improve access to Pemfexy.”
    To learn more about how TailorMed’s Express Enroll solution improves access to financial assistance, please visit https://resources.tailormed.co/tailormed-express-enroll .

Integra Connect to Present Key Clinical Research at the ASCO Quality Care Symposium

Retrieved on: 
Tuesday, October 24, 2023
NSCLC, American Society of Clinical Oncology, III, Biomarker, Water Quality Initiative, UPMC Hillman Cancer Center, Health, Research, AM, Society, Multimedia, Integra, Quality of life, PALM, Medicine, Histology, Abstract, HRR, Immunotherapy, Oncology, Lung cancer, Cancer, Patient, UPMC, ASCO, Nursing, Pharmaceutical industry, Stonemasonry, Medical imaging, MD

WEST PALM BEACH, Fla., Oct. 24, 2023 /PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023. The findings from these three studies – two done in conjunction with UPMC Hillman Cancer Center in Pittsburgh, PA and one done in conjunction with South Carolina Oncology Associates (SCOA) – emphasize the critical role quality initiatives play in identifying gaps in care and driving action to improve patient outcomes. Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.

Key Points: 
  • , the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023.
  • Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.
  • The studies were conducted with Integra Connect as part of its Quality Initiatives program, which is designed to help oncology practices, cancer institutes, and health systems make well-informed clinical decisions to ensure patients are receiving the best possible care.
  • Integra Connect does this by bringing together clinical data from disparate systems and sources, organizing the information into complete, longitudinal patient journeys, and conducting in-depth analyses with its AI-enabled solutions.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Tuesday, October 24, 2023
TKI, Bevacizumab, Patient, Pemetrexed, Arm, PC, NSCLC, Carboplatin, CDX, ESMO, Progression-free survival, III, Therapy, Lung cancer, Cisplatin, PFS, European Society for Medical Oncology, Phenotype, Research, TIL, JCO, Journal, Samsung Medical Center, ALK, Journal of Clinical Oncology, Annual general meeting, Immunotherapy, H&E, ORR, Oncology, ABCP, Mutation, EGFR, Pharmaceutical industry, Medical imaging

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

Retrieved on: 
Monday, October 23, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, DXD, Neoplasm, EGFR, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Lung cancer, Congress, PFS, MD, Docetaxel, European Society for Medical Oncology, CRS, HIV disease progression rates, R, Nausea, ADC, Daiichi Sankyo, Risk, Histology, ORR, ILD, Anemia, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

Retrieved on: 
Monday, October 23, 2023
Research, Technology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Principal, Intelligence, MRI, NSCLC, History, Lung cancer, BHCC, OTC, Organization, Kiromal Katibin, Clinical trial, GDT, CT, PET/CT, Cancer, Patient, Medical imaging, Pharmaceutical industry, MD

Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study.

Key Points: 
  • Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study.
  • The collaboration between Kiromic BioPharma and BHCC underscores the shared commitment between the two organizations to advance the fight against cancer through innovative therapeutic approaches.
  • “The clinical trial agreement is a momentous first step in the development of this important treatment.
  • Lung cancer is by far the leading cause of cancer death in the U.S., accounting for about 1 in 5 of all cancer deaths.